Although most patients who contract COVID-19 recover within a few weeks, a significant amount of people still have symptoms linger for at least three or more months after infection.
Meet Revive Therapeutics (CSE:RVV) a Toronto-based company that has immense potential to capitalize on this under-met market.
As it currently stands, no approved treatment is available for symptoms of long COVID, but Revive Therapeutics could potentially change that landscape.
Case in point, the company recently announced it has locked in a meeting request with the U.S. Food and Drug Administration (FDA) for its Revive LC POC Lateral Flow Test Kit.
Revive advances towards long COVID treatment
In a news release, the company stated the meeting with the FDA is for the purpose of providing feedback on the classification, development and regulatory submission strategy for a point-of-care in vitro diagnostic device that can detect post COVID-19 conditions.
Under its wholly owned subsidiary, Revive Therapeutics is advancing the project as a potential blood biomarker diagnosis that identifies long COVID.
Because there is no FDA-approved long-COVID treatment, Revive Therapeutics’ kit could be a game changer in space. Case in point, roughly 10 per cent of COVID-19 cases result in severe acute respiratory syndrome coronavirus 2 infections.
It is estimated that roughly 200 symptoms have been identified as a result of long COVID, including fatigue, brain fog, breathing difficulties and cardiovascular symptoms such as chest pain, arrhythmias, and even sudden cardiac death.
The company said its upcoming meeting with the FDA is expected to take place June 27.
In addition to its upcoming meeting with the federal agency, the company also stated it has entered into a license agreement with the Lawson Health Research Institute for global exclusive rights to the intellectual property of novel blood biomarkers that make up long COVID.
The intellectual property includes “Blood Biomarkers in Long COVID19″; “Biomarkers in Long COVID19″; and “Diagnosis and Treatment of Long COVID.”
Revive Therapeutics updates
Revive Therapeutics also revealed some corporate updates, including its research and development of Bucillamine which is also being evaluated for the treatment of nerve agent exposure. Essentially nerve agents are chemicals that affect the nervous system and are highly toxic.
Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors and death. Together with the Defence R&D Canada – Suffield Research Centre, an agency of the Canadian Department of National Defence, the company is evaluating Bucillamine as a potential treatment for nerve agent exposure.
Bucillamine is an oral thiol-based drug with anti-inflammatory and antiviral properties, that can potentially treat nerve agent exposure as well as having the potential to treat long COVID.
Revive Therapeutics stated that it aims to advance the clinical development of Bucillamine by using published research from its previous Phase 3 clinical study. As such, the company is preparing a clinical package that includes a proposed Phase 2/3 clinical protocol for long COVID to present to the FDA and international health regulatory bodies.
Last year, the company announced the results of its study evaluating the safety and efficacy of oral Bucillamine in patients with mild to moderate COVID-19.
Join the discussion: Find out what everybody’s saying about this stock on the Revive Therapeutics Ltd. Bullboard investor discussion forum and check out the rest of Stockhouse’s stock forums and message boards.
This is sponsored content issued on behalf of Revive Therapeutics please see the full disclaimer here.
